We are developing a pipeline of theragnostic pairings for oncology indications. AAA’s theragnostic platform involves radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy.
Investigational Candidates in Clinical Development:
LUTATHERA® (USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide)Therapeutic
NETSPOT® (gallium Ga 68 dotatate)PET Diagnostic
SOMAKIT TOC® (gallium (Ga 68) edotreotide)PET Diagnostic
99MTc-rhAnnexin V-128SPECT Diagnostic
CTT105718F PET Diagnostic
LUTATHERA® (USAN: Lutetium Lu 177 dotatate/INN: Lutetium (177Lu) oxodotreotide). LUTATHERA® is a Lu-177-labeled somatostatin analog peptide. LUTATHERA® was approved by the FDA in January 2018, and by the European Commission in September 2017. LUTATHERA® also received orphan drug designation from the FDA and EMA.
NETSPOT® (gallium Ga 68 dotatate) and SOMAKIT TOC® (gallium (Ga 68) edotreotide). NETSPOT® was approved by the FDA in June 2016, and SOMAKIT TOC® was approved by the European Commission in December 2016. These products have received orphan drug designation from the FDA and EMA.
99MTc-rhAnnexin V-128. 99MTc-rhAnnexin V-128 is a Single Photon Emission Computed Tomography (SPECT) investigational candidate for the diagnosis and assessment of apoptotic and necrotic processes, which are present in a number of pathological conditions in oncology and cardiovascular disease, as well as in autoimmune disorders. A Phase I trial of Annexin V-128 was conducted at the University of Ottawa Heart Institute in Canada to assess its safety, tolerability, biodistribution and dosimetry. 99MTc-rhAnnexin V-128 is currently in a Phase I/II trial for the diagnosis of rheumatoid arthritis and ankylosing spondylitis, as well as several Phase II studies in cardiovascular, cardio-oncology, and pulmonary indications.
177LuPSMA-R2 and 68GaPSMA-R2. 177LuPSMA-R2 and 68GaPSMA-R2 are in development to treat, image, monitor and stage prostate cancer. PSMA-R2 is a ligand of Prostate-Specific Membrane Antigen (PSMA), expressed on the majority of prostate tumor cells. 177LuPSMA-R2 is being developed to treat prostate cancer and 68GaPSMA-R2 is under development as its complementary diagnostic candidate. AAA has signed an exclusive license agreement with Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-R2 for prostate cancer.
CTT1057. CTT1057 is an 18F-labeled investigational diagnostic candidate in development for PET imaging of prostate cancer. CTT1057 is a phosphoramidate-based peptide, which specifically binds to Prostate-Specific Membrane Antigen (PSMA), expressed on the majority of prostate tumor cells. AAA has signed an exclusive worldwide license agreement with Cancer Targeted Technology, LLC (CTT) to develop CTT1057 for PET imaging of prostate cancer. A Phase 1 study evaluating the safety, biodistribution and dosimetry of CTT1057 was conducted at the University of California, San Francisco.
177LuNeoBOMB1 and 68GaNeoBOMB1. 177LuNeoBOMB1 and 68GaNeoBOMB1 are new generation antagonist bombesin analogs in development to treat, image, monitor and stage gastrin-releasing peptide receptor (GRPR)-expressing malignancies, such as such as gastrointestinal stromal tumors (GIST), prostate cancer and breast cancer. 177LuNeoBOMB1 is a therapeutic candidate and 68GaNeoBOMB1 is its complementary diagnostic candidate. AAA has signed an exclusive license agreement with Erasmus University Medical Center (UMC) and Demokritos National Center for Scientific Research to develop NeoBOMB1. A Phase 1/2a study of 68GaNeoBOMB1 for diagnostic use in GIST is ongoing, with plans to initiate other diagnostic and therapeutic studies in 2018.